Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P4HB | P07237 | 6/20 | 0.41 |
| ▸ | RXFP1 | Q9HBX9 | 2/20 | 0.41 |
| ▸ | GSK3B | P49841 | 2/20 | 0.39 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.39 |
| ▸ | VNN1 | O95497 | 1/20 | 0.38 |
| ▸ | MRGPRX4 | Q96LA9 | 2/20 | 0.38 |
| ▸ | CYP1A1 | P04798 | 1/20 | 0.38 |
| ▸ | MAOB | P27338 | 1/20 | 0.38 |
| ▸ | CYP1B1 | Q16678 | 1/20 | 0.38 |
| ▸ | ESR1 | P03372 | 1/20 | 0.38 |
| ▸ | NR4A1 | P22736 | 1/20 | 0.37 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.37 |
| ▸ | NR4A3 | Q92570 | 1/20 | 0.37 |
| ▸ | PTPN5 | P54829 | 1/20 | 0.37 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3946826 | 1.00 | P4HB (0.41) | P4HBRXFP1GSK3BPTGDR2VNN1 | |
| SCHEMBL3946828 | 1.00 | P4HB (0.41) | P4HBRXFP1GSK3BPTGDR2VNN1 | |
| SCHEMBL4098610 | 0.92 | RXFP1 (0.46) | P4HBRXFP1GSK3BPTGDR2VNN1 | |
| SCHEMBL4098608 | 0.92 | RXFP1 (0.46) | P4HBRXFP1GSK3BPTGDR2VNN1 | |
| SCHEMBL3940487 | 0.88 | NR1H4 (0.44) | P4HBGSK3BVNN1ESR1NR4A1 | |
| SCHEMBL3940491 | 0.88 | NR1H4 (0.44) | P4HBGSK3BVNN1ESR1NR4A1 | |
| SCHEMBL3938991 | 0.88 | KIF11 (0.47) | P4HBRXFP1PTGDR2VNN1CYP1A1 | |
| SCHEMBL3938986 | 0.88 | KIF11 (0.47) | P4HBRXFP1PTGDR2VNN1CYP1A1 | |
| SCHEMBL3949656 | 0.85 | MRGPRX4 (0.41) | P4HBGSK3BMRGPRX4ESR1 | |
| SCHEMBL3949664 | 0.85 | MRGPRX4 (0.41) | P4HBGSK3BMRGPRX4ESR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090203667-A1 | PENTADIENAMIDE DERIVATIVES | KYOWA HAKKO KIRIN CO., LTD. (JP) | 2009-08-13 | — | — | US | disclosed |
| EP-2050734-A1 | PENTADIENAMIDE DERIVATIVE | Kyowa Hakko Kirin Co., Ltd. (JP) | 2009-04-22 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090203667-A1 | PENTADIENAMIDE DERIVATIVES | PRMT1, REN, NGLY1 | P4HB 793/4885RXFP1 65/4885GSK3B 3499/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.